Poniard Reports Positive Results From Phase II Colorectal Cancer Trial
Posted on: Monday, 2 June 2008, 09:22 CDT
Poniard Pharmaceuticals has reported positive preliminary results from its ongoing randomized Phase II clinical trial in patients with metastatic colorectal cancer.
The randomized, controlled, 100-patient Phase II study is comparing the safety and efficacy of intravenous picoplatin given once every four weeks in combination with 5-fluorouracil and leucovorin in the Folpi regimen with oxaliplatin in combination with 5-fluorouracil and leucovorin in the modified Folfox-6 regimen.
Preliminary data suggest that Folpi and Folfox may have similar anti-tumor activity in metastatic colorectal cancer (CRC). Of 11 evaluable patients in the Folpi arm, 10 achieved disease control (partial response combined with stable disease), including two partial responses. Of 13 evaluable patients in the Folfox arm, 10 achieved disease control, including one partial response. A total of 37 patients across both arms are too early for evaluation.
Robert Jager, chief medical officer of Poniard, said: "These data support our strategy of developing picoplatin as a preferred platinum for the first-line treatment of metastatic CRC. The ongoing Phase II trial could support advancement of picoplatin into a registration trial."
Source: Datamonitor
Related Articles
- Exercise Assist Patients With Non-Alcoholic Fatty Liver Disease
- Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
- BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of Its MOR103 Program
- Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
- Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials With HE3286 in Diseases of Inflammation
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
- Transgene: First Patients Included in TG 1042 (Ad-IFNg) Phase II Clinical Trial in Cutaneous B-Cell Lymphoma
- Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety; Data to Be Analysed for Potential New Clinical Trials
 |
 |
User Comments (0)
RSS Feeds